4//SEC Filing
Zarrabian Saiid 4
Accession 0001213900-17-012230
CIK 0001498382other
Filed
Nov 15, 7:00 PM ET
Accepted
Nov 16, 4:30 PM ET
Size
7.1 KB
Accession
0001213900-17-012230
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Purchase
Common Stock
2017-11-14$0.82/sh+55,000$45,100→ 55,000 total - Purchase
Common Stock
2017-11-14$0.84/sh+5,900$4,956→ 5,900 total(indirect: By Children)
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $0.8015 to $0.8385. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $0.8298 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
DelMar Pharmaceuticals, Inc.
CIK 0001498382
Entity typeother
Related Parties
1- filerCIK 0001495521
Filing Metadata
- Form type
- 4
- Filed
- Nov 15, 7:00 PM ET
- Accepted
- Nov 16, 4:30 PM ET
- Size
- 7.1 KB